

Table 10.1 Selected Kinase Inhibitors in the Market or That Have Entered Clinical Development—cont'd

Type	Target	Agents
		CEP-7055
		Monoclonal antibody Bevacizumab (Avastin [®])
		Soluble decoy receptor Ziv-aflibercept (Zaltrap [®])
		Ribozyme Angiozyme (RPI.4610)
	PDGFRs	Small-molecule inhibitor Suramin (Metaret [®])
	FGFRs	Small-molecule inhibitors Dovitinib (TKI258) BGJ398 (NVP-BGJ398)
		Monoclonal antibody PRO-001
	FLT3 (CD135)	Small-molecule inhibitors Tandutinib (MLN-518, CT-53518) Lestaurtinib (CEP-701) Midostaurin (PKC-412)
	Bcr-Abl	Small-molecule inhibitors ATP mimics Imatinib (STI-571, Glivec [®]) Nilotinib (AMN-107, Tassigna [®]) Radotinib (Supect [®]) Ponatinib (AP24534, Iclusig [®]) Tyrosine mimics Adaphostin (NSC-680410) ON-012380
	Bcr-Abl/Src	Small-molecule inhibitors Dasatinib (BMS-354825, Sprycel [®]) Bosutinib (SKI-606, Bosulif [®]) Saracatinib (AZD-0530)
	Bcr-Abl biosynthesis	Small-molecule inhibitor Omacetaxine mepesuccinate (Synribo [®])
	ALK	Small-molecule inhibitors Crizotinib (PF-02341066, Xalkori [®]) X-376 X-396 Ceritinib (LDK-378, Zykadia [®]) AP26113 CEP-37440 ASP-3026 Alectinib PF-06463922 RXDX-101 (NMS-E628) TSR-011